PA
PASG icon

Parallel Advisors’s Passage Bio PASG Stock Holding History

Parallel Advisors’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$126 Hold
16
– – ﹤0.01% 3779
2025
Q4 		$189 Hold
16
– – ﹤0.01% 3518
2025
Q3 		$128 Buy
+16
New +$111 ﹤0.01% 3470
2022
Q1 		– Sell
-62
Closed -$8K – 3189
2021
Q4 		$8K Buy
62
+56
+933% +$9.14K ﹤0.01% 2218
2021
Q3 		$1K Buy
+6
New +$1.43K ﹤0.01% 2925

Other funds holding PASG

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
YCM
Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Parallel Advisors's PASG Position: Q1 2026 in Review

Parallel Advisors held its Passage Bio (PASG) position steady in Q1 2026 at 16 shares worth $126. The position accounts for ﹤0.01% of the portfolio, ranked #3779.

Parallel Advisors first reported a position in PASG in Q3 2021 and has held it in 5 quarters since. The position peaked at $8K in Q4 2021. 35 funds tracked by Wall St. Rank hold PASG as of Q1 2026.

  • Parallel Advisors held 16 shares of Passage Bio worth $126 as of Q1 2026.
  • Parallel Advisors left its Passage Bio share count unchanged in Q1 2026.
  • Passage Bio made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3779 holding.
  • Parallel Advisors first reported a position in Passage Bio in Q3 2021 and has held it in 5 quarters since.
  • Parallel Advisors's Passage Bio position peaked at $8K in Q4 2021.
  • 35 funds tracked by Wall St. Rank held Passage Bio as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.